Jean-FranÃ§ois ELÃ©ouÃ«t

List of Publications by Year
in descending order

49 papers	2,428 citations	185998 28 h-index	214527 47 g-index
55 all docs	55 docs citations	55 times ranked	2313 citing authors

#	Article	IF	Citations
1	Characterization of the Interaction Domains between the Phosphoprotein and the Nucleoprotein of Human Metapneumovirus. Journal of Virology, 2022, 96, JVI0090921.	1.5	4
2	New Look at RSV Infection: Tissue Clearing and 3D Imaging of the Entire Mouse Lung at Cellular Resolution. Viruses, 2021, 13, 201.	1.5	5
3	Tetramerization of Phosphoprotein Is Essential for Respiratory Syncytial Virus Budding while Its N-Terminal Region Mediates Direct Interactions with the Matrix Protein. Journal of Virology, 2021, 95, .	1.5	15
4	The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2â€™-O-methylation. PLoS Pathogens, 2021, 17, e1009562.	2.1	11
5	Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis. Frontiers in Immunology, 2021, 12, 683902.	2.2	5
6	A condensate-hardening drug blocks RSV replication in vivo. Nature, 2021, 595, 596-599.	13.7	121
7	Pulmonary mesenchymal stem cells are engaged in distinct steps of host response to respiratory syncytial virus infection. PLoS Pathogens, 2021, 17, e1009789.	2.1	6
8	A Structural and Dynamic Analysis of the Partially Disordered Polymerase-Binding Domain in RSV Phosphoprotein. Biomolecules, 2021, 11, 1225.	1.8	6
9	Depletion of TAX1BP1 Amplifies Innate Immune Responses during Respiratory Syncytial Virus Infection. Journal of Virology, 2021, 95, e0091221.	1.5	6
10	Avian Cell Line DuckCeltÂ®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate MetavacÂ®. Vaccines, 2021, 9, 1190.	2.1	6
11	Interactions between the Nucleoprotein and the Phosphoprotein of Pneumoviruses: Structural Insight for Rational Design of Antivirals. Viruses, 2021, 13, 2449.	1.5	7
12	Targeting the Respiratory Syncytial Virus N 0 -P Complex with Constrained Î±-Helical Peptides in Cells and Mice. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	5
13	Minimal Elements Required for the Formation of Respiratory Syncytial Virus Cytoplasmic Inclusion Bodies In Vivo and In Vitro. MBio, 2020, 11, .	1.8	65
14	De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science, 2020, 368, .	6.0	137
15	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Research, 2020, 177, 104774.	1.9	30
16	Interferon-Induced Protein 44 and Interferon-Induced Protein 44-Like Restrict Replication of Respiratory Syncytial Virus. Journal of Virology, 2020, 94, .	1.5	49
17	A small fragmented P protein of respiratory syncytial virus inhibits virus infection by targeting P protein. Journal of General Virology, 2020, 101, 21-32.	1.3	5
18	High-throughput screening of active compounds against human respiratory syncytial virus. Virology, 2019, 535, 171-178.	1.1	5

#	Article	IF	Citations
19	The Interactome analysis of the Respiratory Syncytial Virus protein M2-1 suggests a new role in viral mRNA metabolism post-transcription. Scientific Reports, 2019, 9, 15258.	1.6	14
20	Structure of the Respiratory Syncytial Virus Polymerase Complex. Cell, 2019, 179, 193-204.e14.	13.5	108
21	Biochemical characterization of the respiratory syncytial virus N0-P complex in solution. Journal of Biological Chemistry, 2019, 294, 3647-3660.	1.6	22
22	Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biology, 2019, 17, e3000164.	2.6	26
23	First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies. Veterinary Research, 2018, 49, 118.	1.1	5
24	The Structure of the Human Respiratory Syncytial Virus M2-1 Protein Bound to the Interaction Domain of the Phosphoprotein P Defines the Orientation of the Complex. MBio, 2018, 9, .	1.8	28
25	RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription. PLoS Pathogens, 2018, 14, e1006920.	2.1	57
26	New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners. Journal of Biological Chemistry, 2017, 292, 2120-2131.	1.6	49
27	A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	35
28	Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus. Nature Communications, 2017, 8, 563.	5.8	141
29	RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 411-420.	1.7	28
30	Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept. Journal of Controlled Release, 2016, 243, 146-159.	4.8	21
31	Interactome Analysis of the Human Respiratory Syncytial Virus RNA Polymerase Complex Identifies Protein Chaperones as Important Cofactors That Promote L-Protein Stability and RNA Synthesis. Journal of Virology, 2015, 89, 917-930.	1.5	65
32	Fine Mapping and Characterization of the L-Polymerase-Binding Domain of the Respiratory Syncytial Virus Phosphoprotein. Journal of Virology, 2015, 89, 4421-4433.	1.5	45
33	A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. BMC Veterinary Research, 2015, 11, 76.	0.7	30
34	Identification and Characterization of the Binding Site of the Respiratory Syncytial Virus Phosphoprotein to RNA-Free Nucleoprotein. Journal of Virology, 2015, 89, 3484-3496.	1.5	60
35	A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus. Journal of Virology, 2015, 89, 11129-11143.	1.5	56
36	Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies. PLoS ONE, 2014, 9, e100392.	1.1	34

#	Article	IF	Citations
37	Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1580-1585.	3.3	58
38	A Novel Subnucleocapsid Nanoplatform for Mucosal Vaccination against Influenza Virus That Targets the Ectodomain of Matrix Protein 2. Journal of Virology, 2014, 88, 325-338.	1.5	52
39	Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nature Communications, 2014, 5, 5104.	5.8	102
40	The respiratory syncytial virus nucleoproteinâ€“RNA complex forms a left-handed helical nucleocapsid. Journal of General Virology, 2013, 94, 1734-1738.	1.3	90
41	Structure and Functional Analysis of the RNA- and Viral Phosphoprotein-Binding Domain of Respiratory Syncytial Virus M2-1 Protein. PLoS Pathogens, 2012, 8, e1002734.	2.1	70
42	Characterization of a Viral Phosphoprotein Binding Site on the Surface of the Respiratory Syncytial Nucleoprotein. Journal of Virology, 2012, 86, 8375-8387.	1.5	64
43	The Insertion of Fluorescent Proteins in a Variable Region of Respiratory Syncytial Virus L Polymerase Results in Fluorescent and Functional Enzymes But with Reduced Activities. The Open Virology Journal, 2011, 5, 103-108.	1.8	47
44	A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine, 2010, 28, 3722-3734.	1.7	37
45	The Respiratory Syncytial Virus M2-1 Protein Forms Tetramers and Interacts with RNA and P in a Competitive Manner. Journal of Virology, 2009, 83, 6363-6374.	1.5	75
46	Crystal Structure of a Nucleocapsid-Like Nucleoprotein-RNA Complex of Respiratory Syncytial Virus. Science, 2009, 326, 1279-1283.	6.0	290
47	Sub-Nucleocapsid Nanoparticles: A Nasal Vaccine against Respiratory Syncytial Virus. PLoS ONE, 2008, 3, e1766.	1.1	47
48	The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. Journal of General Virology, 2007, 88, 196-206.	1.3	82
49	Biochemical characterization of the respiratory syncytial virus Pâ€“P and Pâ€“N protein complexes and localization of the P protein oligomerization domain. Journal of General Virology, 2004, 85, 1643-1653.	1.3	94